Abstract:Background: The use of single-chain variable fragments (scFvs) for treating human diseases, such as cancer and immune system disorders, has attracted significant attention. However, a critical drawback of scFv is its extremely short serum half-life, which limits its therapeutic potential. Thus, there is a critical need to prolong the serum half-life of the scFv for clinical applications. One promising serum half-life extender for therapeutic proteins is human serum albumin (HSA), which is the most abundant protein in human serum, known to have an exceptionally long serum half-life. However, conjugating a macromolecular half-life extender to a small protein, such as scFv, often results in a significant loss of its critical properties. Results: In this study, we conjugated the HSA to a permissive site of scFv to improve pharmacokinetic profiles. To ensure minimal damage to the antigen-binding capacity of scFv upon HSA conjugation, we employed a site-specific conjugation approach using a heterobifunctional crosslinker that facilitates thiol-maleimide reaction and inverse electron-demand Diels-Alder reaction (IEDDA). As a model protein, we selected 4D5scFv, derived from trastuzumab, a therapeutic antibody used in human epithermal growth factor 2 (HER2)-positive breast cancer treatment. We introduced a phenylalanine analog containing a very reactive tetrazine group (frTet) at conjugation site candidates predicted by computational methods. Using the linker TCO-PEG4-MAL, a single HSA molecule was site-specifically conjugated to the 4D5scFv (4D5scFv-HSA). The 4D5scFv-HSA conjugate exhibited HER2 binding affinity comparable to that of unmodified 4D5scFv. Furthermore, in pharmacokinetic profile in mice, the serum half-life of 4D5scFv-HSA was approximately 12 h, which is 85 times longer than that of 4D5scFv. Conclusions: The antigen binding results and pharmacokinetic profile of 4D5scFv-HSA demonstrate that the site-specifically albumin-conjugated scFv retained its binding affinity with a prolonged serum half-life. In conclusion, we developed an effective strategy to prepare site-specifically albumin-conjugated 4D5scFv, which can have versatile clinical applications with improved efficacy.

AlbuCatcher for Long-Acting Therapeutics

Antibody Capture with Twin-Column Continuous Chromatography: Effects of Residence Time, Protein Concentration and Resin

Mixed-Mode Expanded-Bed Adsorption for Human Serum Albumin Separation

Enhanced therapeutic potential of antibody fragment via IEDDA-mediated site-specific albumin conjugation

Human serum albumin binders: A piggyback ride for long-acting therapeutics

Albumin-binding as a universal strategy for half-life extension

An Albumin Sandwich Enhances in Vivo Circulation and Stability of Metabolically Labile Peptides

Albumin affibody-outfitted injectable gel enabling extended release of urate oxidase-albumin conjugates for hyperuricemia treatment

Serum albumin-binding VH Hs with variable pH sensitivities enable tailored half-life extension of biologics

Albumin-based drug delivery: harnessing nature to cure disease

Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy.

Small Bispecific Affinity Proteins for Simultaneous Target Binding and Albumin-Associated Half-Life Extension

Recent Advances on the Development of Pharmacotherapeutic Agents on the Basis of Human Serum Albumin

Generation of therapeutic protein variants with the human serum albumin binding capacity via site-specific fatty acid conjugation

Prolonging the Plasma Circulation of Proteins by Nano-Encapsulation with Phosphorylcholine-Based Polymer

Half-life extension using serum albumin-binding DARPin® domains

Albumin-based potential drugs: focus on half-life extension and nanoparticle preparation

In Vivo Half-Life Extension of BMP1/TLL Metalloproteinase Inhibitors Using Small-Molecule Human Serum Albumin Binders.

Subcutaneous Delivery of Albumin: Impact of Thermosensitive Hydrogels

Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment

Tuning protein half-life in mouse using sequence-defined biopolymers functionalized with lipids